SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

  • Org Study ID: XmAb20717-01
  • Secondary ID: DUET-2
  • NCT ID: NCT03517488
  • NCT Alias:
  • Sponsor: Xencor, Inc. - Industry
  • Source: Xencor, Inc.

Brief Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Overal Status Start Date Phase Study Type
Recruiting July 10, 2018 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Determine the safety and tolerability profile of XmAb20717

Primary Outcome 1 - Time Frame: 56 Days


  • Melanoma
  • Breast Carcinoma
  • Hepatocellular Carcinoma
  • Urothelial Carcinoma
  • Squamous Cell Carcinoma of the Head and Neck
  • Renal Cell Carcinoma
  • Colorectal Carcinoma
  • Non-small Cell Lung Carcinoma
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • Endometrial Carcinoma
  • Mesothelioma
  • Neuroendocrine Carcinoma
  • Cervical Cancer
  • Small Cell Lung Carcinoma
  • Squamous Cell Carcinoma of the Anus
  • Castration-Resistant Prostate Carcinoma
  • Nasopharyngeal Carcinoma
  • Cholangiocarcinoma
  • Basal Cell Carcinoma
  • Ovarian Carcinoma
  • Fallopian Tube Carcinoma
  • Thymoma
  • Thymic Carcinoma
  • Squamous Cell Carcinoma of the Penis
  • Vulvar Carcinoma
  • Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy
  • Malignant Adnexal Neoplasms
  • Non-squamous Cell Salivary Gland Carcinoma


Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of one of the following advanced
solid tumors:

PART A (Dose Escalation Cohorts)

1. Melanoma;

2. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative
(triple-negative breast cancer; TNBC);

3. Hepatocellular carcinoma;

4. Urothelial carcinoma;

5. Squamous cell carcinoma of the head and neck;

6. Renal cell carcinoma (clear cell predominant type);

7. Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or
endometrial carcinoma;

8. Non-small cell lung carcinoma;

9. Gastric or gastroesophageal junction adenocarcinoma

10. Mesothelioma;

11. High-grade neuroendocrine carcinoma, including small cell carcinoma of the lung

12. Cervical cancer;

13. Squamous cell carcinoma of the anus

PART B (Dose Expansion Cohorts):

1. Melanoma

2. Renal cell carcinoma (clear cell predominant type)

3. Non-small cell lung carcinoma

4. Castrate-resistant adenocarcinoma of the prostate, defined as progressive disease
after surgical castration, or progression in the setting of medical androgen ablation
with a castrate level of testosterone (< 50 ng/dL)

5. Nasopharyngeal carcinoma

6. Cholangiocarcinoma

7. Basal cell carcinoma

8. Squamous cell carcinoma of the anus

9. Mesothelioma

10. Ovarian or fallopian tube carcinoma

11. Malignant adnexal neoplasms (including, but not limited to, sebaceous carcinoma,
trichilemmal carcinoma, pilomatrix carcinoma, eccrine carcinoma, hidradenocarcinoma,
adnexal carcinoma with divergent differentiation, papillary digital eccrine
adenocarcinoma, microcystic adnexal carcinoma, and clear cell eccrine carcinoma)

12. Thymoma

13. Thymic carcinoma

14. Squamous cell carcinoma of the penis

15. Neuroendocrine carcinoma

16. Vulvar cancer

17. Non-squamous cell salivary gland carcinoma (except adenoid cystic carcinoma)

18. Subjects with other solid tumors for which there is published evidence of anti-tumor
activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy but for which there is
no FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment may be
eligible for Part B after approval by the Medical Monitor.

- All subjects' cancer must have progressed after treatment with all standard
therapies or have no appropriate available therapies.

- Subjects, except those with adenocarcinoma of the prostate, must have measurable
disease by RECIST 1.1.

- Have available adequate archival formalin-fixed paraffin-embedded block(s)/slides
containing tumor or adequate pre-dose fresh tumor biopsy tissue

- ECOG performance status of 0 - 1

- Subjects with adenocarcinoma of the prostate must have evaluable disease
(measurable or nonmeasurable lesions) by PCWG3.

Exclusion Criteria:

- Subjects currently receiving other anticancer therapies, with the exception of
subjects with adenocarcinoma of the prostate, who may continue luteinizing
hormone-releasing hormone (LHRH) analogue therapy.

- Treatment with any CTLA4 antibody within 6 weeks of the start of study drug.

- Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the
start of study drug.

- Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort

- Treatment with any other anticancer therapy within 2 weeks of the start of study drug
(i.e., other immunotherapy, chemotherapy, radiation therapy, etc.). Subjects with
prostate cancer may continue LHRH analogue therapy.

- A life-threatening (Grade 4) immune-mediated AE related to prior immunotherapy.

- Failure to recover from any immune-related toxicity from prior cancer therapy to ≤
Grade 1, except if previous immune-related endocrinopathy is medically managed with
hormone replacement therapy only.

- Failure to recover from any other toxicity (other than immune-related toxicity)
related to previous anticancer treatment to ≤ Grade 2.

- Have known active CNS metastases and/or carcinomatous meningitis. Participants with
previously treated brain metastases may participate provided they are radiologically
stable, ie, are without evidence of progression for at least 4 weeks by repeat
imaging, are clinically stable, and without requirement of steroid treatment for at
least 14 days prior to first dose of study treatment.

- Active known or suspected autoimmune disease (except that subjects are permitted to
enroll if they have vitiligo; type 1 diabetes mellitus or residual hypothyroidism due
to an autoimmune condition that is treatable with hormone replacement therapy only;
psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed
without systemic therapy; or arthritis that is managed without systemic therapy beyond
oral acetaminophen and non-steroidal anti-inflammatory drugs).

- Has any condition requiring systemic treatment with corticosteroids, prednisone
equivalents, or other immunosuppressive medications within 14 days prior to first dose
of study drug (except that inhaled or topical corticosteroids or brief courses of
corticosteroids given for prophylaxis of contrast dye allergic response are

- Receipt of an organ allograft.

- Prior treatment with any checkpoint inhibitor therapy regimen that targets both PD1/L1
and CTLA-4.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Barbara Hickingbottom, MD

Role: Study Director

Affiliation: Xencor, Inc.

Overall Contact

Name: Barbara Hickingbottom, MD

Phone: 858-480-3413



Facility Status Contact
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California 90048
United States
UCLA Hematology-Oncology Clinic (Westwood)
Los Angeles, California 90095
United States
University of California San Diego Moores Cancer Center
San Diego, California 92093-0698
United States
University of California San Francisco Medical Center
San Francisco, California 94115
United States
Emory University
Atlanta, Georgia 30322
United States
University of Chicago Medicine
Chicago, Illinois 60637
United States
Active, not recruiting
The University of Kansas Clinical Research Center
Fairway, Kansas 66205
United States
Karmanos Cancer Institute
Detroit, Michigan 48201
United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York 10016
United States
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York 10032
United States
Providence Portland Medical Center
Portland, Oregon 97213
United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania 19104
United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania 15232
United States
The University of Texas MD Anderson Cancer Center
Houston, Texas 77030
United States
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah 84112
United States
Emily Couric Clinical Cancer Center
Charlottesville, Virginia 22903
United States
Seattle Cancer Care Alliance
Seattle, Washington 98109
United States